Condition

Pancreatic Cancer

Find a Doctor

Gauri R. Varadhachary
GV
Areas of Expertise

Gauri R. Varadhachary

University Of Texas M. D. Anderson Cancer Center
Oncology, Hematology, Internal Medicine
Female

Bio

Gauri Varadhachary is an Oncologist and an Internal Medicine specialist in Houston, Texas. Dr. Varadhachary is a global expert in Pancreatic Cancer. She has been an author on 164 peer reviewed articles and participated in 2 clinical trials in the past 15 years. In particular, she has been an author on 111 peer reviewed articles and participated in 2 clinical trials regarding Pancreatic Cancer. She is licensed to treat patients in TX.

Areas of Expertise

Contact

6410 Fannin St
230
Houston, TX 77030, US

713-704-3961

Latest Advances

Latest Advance
Study
  • Condition: Advanced Pancreatic Ductal Adenocarcinoma
  • Journal: Cancer medicine
  • Treatment Used: Modified Gemcitabine plus Nab-Paclitaxel Regimen
  • Number of Patients: 235
  • Published —
This study review the safety and effectiveness of a modified gemcitabine plus nab-paclitaxel regimen in patients with advanced pancreatic ductal adenocarcinoma.
Latest Advance
Study
  • Condition: Advanced Rare Cancers
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Pembrolizumab
  • Number of Patients: 127
  • Published —
In this study, researchers evaluated the safety and effectiveness of pembrolizumab for the treatment of advanced rare cancers.
Latest Advance
Study
  • Condition: Pancreatic Ductal Adenocarcinoma
  • Journal: Annals of surgery
  • Treatment Used: Postoperative Chemotherapy after Preoperative Therapy and Pancreatectomy
  • Number of Patients: 245
  • Published —
This study tested the safety and efficacy of using a postoperative chemotherapy after a preoperative therapy and pancreatectomy to treat patients with pancreatic ductal adenocarcinoma.
Latest Advance
Study
  • Condition: Advanced Biliary Tract Cancers
  • Journal: JAMA oncology
  • Treatment Used: Gemcitabine, Cisplatin, and nab-Paclitaxel
  • Number of Patients: 60
  • Published —
In this study, researchers evaluated the outcomes of adding nab-paclitaxel to gemcitabine-cisplatin for the treatment of advanced biliary tract cancer.
Latest Advance
Study
  • Condition: Small Bowel Adenocarcinoma (SBA)
  • Journal: The oncologist
  • Treatment Used: Taxane-Based Therapy
  • Number of Patients: 20
  • Published —
This study characterized the activity of taxanes in the treatment of small bowel adenocarcinoma (SBA).
Latest Advance
Study
  • Condition: BRAF-Mutated Melanoma
  • Journal: Cancer
  • Treatment Used: Vemurafenib, Carboplatin, and Paclitaxel Combination Chemotherapy
  • Number of Patients: 19
  • Published —
This study tested the safety and efficacy of using a vemurafenib, carboplatin, and paclitaxel combination chemotherapy to treat patients with BRAF-mutated melanoma and other advanced malignancies.
Latest Advance
Study
  • Condition: Pancreatic Ductal Adenocarcinoma
  • Journal: Annals of surgical oncology
  • Treatment Used: Gemcitabine and Nab-Paclitaxel Chemotherapy
  • Number of Patients: 99
  • Published —
In this study, researchers evaluated the effects of gemcitabine and nab-paclitaxel on the outcomes of persons with pancreatic ductal adenocarcinoma.

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 28
  • Start Date: March 2020
Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Radiation, Drug
  • Participants: 68
  • Start Date: March 2015
A Randomized Multicenter Ib/II Study to Assess the Safety & Immunological Effect of Chemoradiation Therapy in Combination With Pembrolizumab Compared to CRT Alone Resectable/Borderline Resectable Pancreatic Cancer

All Publications
View All

Publication
Study
  • Journal: Cancers
  • Published —
Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.
Publication
Study
  • Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • Published —
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.

Contact

6410 Fannin St
230
Houston, TX 77030, US

713-704-3961

Credentials

  • Licenses
    Internal Medicine in TX

Insurance

Contact them to find out if they accept your insurance plan.